APOL1 and kidney disorder: In particular, several inhibitors of APOL1 are in various stages of development—if APOL1 high-risk genotypes are directly associated with the pathogenesis of sepsis external to pre-existing severe renal disease or other organ system dysfunction, such drugs could be offered to high-risk patients to prevent or treat the occurrence of sepsis in scenarios of acute infection (Friedman et al., 2022).